Imunon (IMNN) 10-K 28 Mar 24 2023 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Mar. 26, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-15911
Entity Registrant Name	IMUNON, INC.
Entity Central Index Key	0000749647
Entity Tax Identification Number	52-1256615
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	997 LENOX DRIVE
Entity Address, Address Line Two	SUITE 100
Entity Address, City or Town	LAWRENCEVILLE
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08648
City Area Code	(609)
Local Phone Number	896-9100
Title of 12(b) Security	Common Stock, Par Value $0.01 Per Share
Trading Symbol	IMNN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 11.9
Entity Common Stock, Shares Outstanding		9,399,789
Documents Incorporated by Reference	None
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Name	WithumSmith+Brown, PC
Auditor Location	East Brunswick, New Jersey
Auditor Firm ID	100

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 5,838,566	$ 11,492,841
Investment in debt securities - available for sale, at fair value	9,857,087	21,254,485
Accrued interest receivable on investment securities		128,932
Money market investments, restricted cash		1,500,000
Advances and deposits on clinical programs and other current assets	2,545,051	2,403,433
Total current assets	18,240,704	36,779,691
Property and equipment (at cost, less accumulated depreciation and amortization)	751,906	548,301
Other assets:
Money market investments, restricted cash		4,500,000
Deferred income tax asset	1,280,385	1,567,026
Operating lease right-of-use assets, net	1,595,074	155,876
Deposits and other assets	50,000	425,000
Total other assets	2,925,459	6,647,902
Total assets	21,918,069	43,975,894
Current liabilities:
Accounts payable – trade	3,515,192	3,586,623
Other accrued liabilities	3,390,521	4,794,936
Notes payable – current portion, net of deferred financing costs		1,424,774
Operating lease liabilities - current portion	485,421	230,749
Total current liabilities	7,391,134	10,037,082
Notes payable – non-current portion, net of deferred financing costs		4,610,946
Operating lease liabilities - non-current portion	1,139,293
Total liabilities	8,530,427	14,648,028
Commitments and contingencies
Stockholders’ equity:
Preferred Stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at December 31, 2023 and 2022)
Common stock - $0.01 par value (112,500,000 shares authorized; 9,399,811 and 7,436,219 shares issued at December 31, 2023 and 2022, respectively, and 9,399,789 and 7,436,197 shares outstanding at December 31, 2023 and 2022, respectively)	93,998	74,362
Additional paid-in capital	401,500,838	397,980,023
Accumulated other comprehensive income	60,796	26,494
Accumulated deficit	(388,182,802)	(368,667,825)
Total stockholders’ equity before treasury stock	13,472,830	29,413,054
Treasury stock, at cost (22 shares at December 31, 2023 and 2022)	(85,188)	(85,188)
Total stockholders’ equity	13,387,642	29,327,866
Total liabilities and stockholders’ equity	$ 21,918,069	$ 43,975,894

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	112,500,000	112,500,000
Common stock, shares issued	9,399,811	7,436,219
Common stock, shares outstanding	9,399,789	7,436,197
Treasury stock, shares	22	22

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Licensing revenue		$ 500,000
Operating expenses:
Research and development	11,287,691	11,733,666
General and administrative	9,742,739	13,687,899
Total operating expenses	21,030,430	25,421,565
Loss from operations	(21,030,430)	(24,921,565)
Other income (expense):
Gain from change in earn-out milestone liability		5,396,000
Impairment of in-process research and development		(13,366,234)
Loss on debt extinguishment	(329,158)
Investment income, net	1,157,625	453,356
Interest expense	(197,080)	(5,028,618)
Other (loss) income	(396,319)	1,801
Total other income (expense), net	235,068	(12,543,695)
Loss before income tax benefit	(20,795,362)	(37,465,260)
Income tax benefit	1,280,385	1,567,026
Net loss	$ (19,514,977)	$ (35,898,234)
Net loss per common share - Basic	$ (2.16)	$ (5.03)
Net loss per common share - Diluted	$ (2.16)	$ (5.03)
Weighted average common shares outstanding - Basic	9,045,320	7,142,970
Weighted average common shares outstanding - Diluted	9,045,320	7,142,970

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Changes in:
Realized gains on investment securities recognized in investment income, net	$ 431,801	$ 49,222
Unrealized losses on investment securities, net	(397,499)	(14,754)
Change in realized and unrealized gains on available for sale securities, net	34,302	34,468
Net loss	(19,514,977)	(35,898,234)
Total comprehensive loss	$ (19,480,675)	$ (35,863,766)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (19,514,977)	$ (35,898,234)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	248,154	196,510
Amortization of right-of-use assets	471,851	535,119
Recognition of deferred revenue		(500,000)
Realized and unrealized losses, net, on investment securities	34,302	34,468
Change in fair value of earn-out milestone liability		(5,396,000)
Stock-based compensation	759,013	2,673,047
Change of deferred income tax asset	286,641	(183,580)
Loss on extinguishment of debt	329,158
Write-off of note receivable (Transomic)	375,000
Impairment of in-process research and development		13,366,234
Amortization of deferred finance charges and debt discount associated with note payable	55,122	181,259
Net changes in:
Accrued interest receivable on investment securities	68,136	(20,088)
Advances, deposits, and other current assets	(141,619)	43,980
Other assets		(241,511)
Accounts payable and accrued liabilities	(1,992,929)	2,111,901
Net cash used in operating activities	(19,022,148)	(23,096,895)
Cash flows from investing activities:
Purchases of investment securities	(13,541,806)	(48,226,390)
Proceeds from sale and maturity of investment securities	25,000,000	56,775,000
Purchases of property and equipment	(451,759)	(267,800)
Net cash provided by investing activities	11,006,435	8,280,810
Cash flows from financing activities:
Proceeds from redeemable convertible preferred stock offering		28,500,000
Payment upon redemption of redeemable convertible preferred stock		(28,500,000)
Proceeds from sale of common stock equity, net of issuance costs	2,781,438	6,722,654
Payoff of the SVB loan and accrued end-of-term fees	(6,420,000)
Net cash (used in) provided by financing activities	(3,638,562)	6,722,654
Net change in cash, cash equivalents and restricted cash	(11,654,275)	(8,093,431)
Cash, cash equivalents and restricted cash at beginning of year	17,492,841	25,586,272
Cash, cash equivalents and restricted cash at end of year	5,838,566	17,492,841
Supplemental disclosure of cash flow information:
Income taxes paid	2,500	2,000
Interest	179,542	4,847,359
Non-Cash Investing and Financing Activities
Recognition of right of use asset and liability	$ 1,911,049

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Series Aand B Preferred Stock [Member] Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021		$ 57,705	$ 388,600,979	$ (85,188)	$ (7,974)	$ (332,769,591)	$ 55,795,931
Balance, shares at Dec. 31, 2021		5,770,516		22
Net loss						(35,898,234)	(35,898,234)
Sale of equity through equity financing facilities		$ 16,644	6,706,010				6,722,654
Sale of equity through equity financing facilities, shares		1,664,349
Realized and unrealized gains, net, on investment securities					34,468		34,468
Stock-based compensation expense			2,673,034				2,673,034
Effect of reverse stock split
Effect of reverse stock split, shares		(27)
Issuance of preferred stock upon financing	$ 28,500,000						28,500,000
Issuance of preferred stock upon financing, shares	100,000
Redemption of preferred stock	$ (28,500,000)						(28,500,000)
Redemption of preferred stock, shares	(100,000)
Issuance of common stock for restricted options		$ 13					13
Issuance of common stock for restricted options, shares		1,381
Balance at Dec. 31, 2022		$ 74,362	397,980,023	$ (85,188)	26,494	(368,667,825)	29,327,866
Balance, shares at Dec. 31, 2022		7,436,219		22
Net loss						(19,514,977)	(19,514,977)
Sale of equity through equity financing facilities		$ 19,041	2,762,397				2,781,438
Sale of equity through equity financing facilities, shares		1,904,142
Issuance of common stock upon exercise of restricted options		$ 595					595
Issuance of common stock upon exercise of restricted options, shares		59,450
Realized and unrealized gains, net, on investment securities					34,302		34,302
Stock-based compensation expense			758,418				$ 758,418
Effect of reverse stock split, shares							(5,770,516)
Balance at Dec. 31, 2023		$ 93,998	$ 401,500,838	$ (85,188)	$ 60,796	$ (388,182,802)	$ 13,387,642
Balance, shares at Dec. 31, 2023		9,399,811		22

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure [Table]
Net Income (Loss) Attributable to Parent	$ (19,514,977)	$ (35,898,234)

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Dec. 31, 2023
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business On September 19, 2022, Celsion Corporation announced a corporate name change to Imunon, Inc. (“Imunon” or the “Company”) reflecting the evolution of the Company’s business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company’s common stock continues to trade on the Nasdaq Stock Market under the ticker symbol “IMNN.” Imunon is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across four modalities. The first modality, TheraPlas ® ® ® ® The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting IND-enabling preclinical studies for the development of a COVID-19 booster vaccine (IMNN-101) and a treatment for the Lassa virus (IMNN-102). The Company has also initiated preclinical work to develop a Trp2 tumor associated antigen cancer vaccine in melanoma (IMNN-201). Imunon will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. Basis of Presentation The accompanying consolidated financial statements (“Financial Statements”) of Imunon have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and CLSN Laboratories, Inc. The Company in 2023 dissolved Celsion GmbH. All significant intercompany balances and transactions have been eliminated in consolidation. Events and conditions arising subsequent to the most recent balance sheet date through the date of the issuance of these Financial Statements have been evaluated for their possible impact on the Financial Statements and accompanying notes. No events and conditions would give rise to any information that required accounting recognition or disclosure in the Financial Statements other than those arising in the ordinary course of business. Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the earn-out milestone liabilities, estimates for contingent liabilities, if any, and accounting for impairment of in-process research and development assets. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates. Revenue Recognition The Company’s sole revenue stream was related to the Hisun agreement described in Note 18, and whose contract has expired. There were no Cash and Cash Equivalents Cash and cash equivalents include cash on hand and investments purchased with an original maturity of three months or less. A portion of these funds are not covered by FDIC insurance. Fair Value of Financial Instruments The carrying values of financial instruments approximate their respective fair values. Management believes that the carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments. Short-term investments are recorded at their estimated fair value. Short-Term Investments The Company classifies its investments in debt securities with readily determinable fair values as investments available-for-sale in accordance with Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided over the estimated useful lives of the related assets, ranging from three seven years 248,000 197,000 The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered impaired if its carrying amount exceeds the future net undiscounted cash flows that the asset is expected to generate. If such asset is considered to be impaired, the impairment recognized is the amount by which the carrying amount of the asset, if any, exceeds its fair value determined using a discounted cash flow model. There was no Deposits Deposits include real property security deposits and other deposits which are contractually required and of a long-term nature. In-Process Research and Development, Other Intangible Assets and Goodwill During 2014, the Company acquired certain assets of EGEN, Inc. As more fully described in Note 6, the acquisition was accounted for under the acquisition method of accounting which required the Company to perform an allocation of the purchase price to the assets acquired and liabilities assumed. Under the acquisition method of accounting, the total purchase price is allocated to net tangible and intangible assets and liabilities based on their estimated fair values as of the acquisition date. Impairment or Disposal of Long-Lived Assets The Company assesses the impairment of its long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. See Note 5 for information on impairment losses of its in - Comprehensive Income (Loss) ASC 220, Comprehensive Income Research and Development Research and development costs are expensed as incurred. Equipment and facilities acquired for research and development activities that have alternative future uses are capitalized and charged to expense over their estimated useful lives. Net Loss per Share of Common Stock Basic and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive. For the years ended December 31, 2023 and 2022, the total number of shares of common stock issuable upon exercise of warrants and equity awards was 1,255,642 988,389 Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in results of operations in the period that the tax rate change occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In accordance with ASC 740, Income Taxes, As more fully discussed in Note 10, on November 28, 2023, the Company received approval from the New Jersey Economic Development Authority to sell $ 1.3 1.3 1.3 1.6 1.6 15 20 0.4 Stock-Based Compensation In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, Compensation-Stock Compensation Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued accounting pronouncements will not have a material impact on the Company’s consolidated financial position, results of operations, and cash flows, or do not apply to its operations. In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures

FINANCIAL CONDITION AND GOING C

FINANCIAL CONDITION AND GOING CONCERN UNCERTAINTY	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
FINANCIAL CONDITION AND GOING CONCERN UNCERTAINTY	2. FINANCIAL CONDITION AND GOING CONCERN UNCERTAINTY Since inception, the Company has incurred substantial operating losses, principally from expenses associated with the Company’s research and development programs, clinical trials conducted in connection with the Company’s drug candidates, and applications and submissions to the FDA. The Company has not generated significant revenue and has incurred significant net losses in each year since inception. For the year ended December 31, 2023, the Company had a net loss of $ 19.5 19.0 388 15.7 1.3 The Company expects its operating losses to continue for the foreseeable future as it continues its product development efforts, and when it undertakes marketing and sales activities. The Company’s ability to achieve profitability is dependent upon its ability to obtain governmental approvals, manufacture, and market and sell its new drug candidates. There can be no assurance that the Company will be able to commercialize its technology successfully or that profitability will ever be achieved. The Company expects that its operating results will fluctuate significantly in the future and will depend on a number of factors, many of which are outside the Company’s control. The Company’s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U.S. and worldwide resulting from the COVID-19 pandemic, the Russian invasion of Ukraine and the unrest in the Middle East. The Company continues to monitor its operating activities in light of these events, and it is possible that these events could result in a variety of risks to the business. The specific impact, if any, is not readily determinable as of the date of these consolidated Financial Statements. The Company has based its estimates on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company’s shares or debt, the sale of the Company’s New Jersey NOLs and other sources. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of existing stockholders may be diluted. The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company’s control. These factors include the progress of research activities; the number and scope of research programs; the progress of preclinical and clinical development activities; the progress of the development efforts of parties with whom the Company has entered into research and development agreements; the costs associated with additional clinical trials of drug candidates; the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements; the ability to achieve milestones under licensing arrangements; the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and the costs and timing of regulatory approvals. The consolidated financial statements have been prepared on the going concern basis. In making this assessment, management conducted a comprehensive review of the Company’s business plan including, but not limited to: ● the Company’s financial position for the year ended December 31, 2023; ● significant events and transaction the Company has entered into since December 31, 2023; ● the Company’s cash flow and cash usage forecasts for the period one year from the issuance date of this Annual Report on Form 10-K; ● the Company’s capitalization structure including common stock outstanding and common stock issuable on exercise of warrants and equity awards, and other common stock issuable under equity plans; and ● continued support of the Company’s stockholders. As a result of the uncertainties involved in our business, we are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our research and development projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business. Our estimated future capital requirements are uncertain and could change materially as a result of many factors, including the progress of our research, development, clinical, manufacturing, and commercialization activities. Management has determined the Company has suffered recurring losses from operations and has an accumulated deficit that raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance date of this Annual Report on Form 10-K. The report of our independent registered public accounting firm for the year ended December 31, 2023 includes an explanatory paragraph, which expresses substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of the uncertainty. A fundamental component of the ability to continue as a going concern is the Company’s ability to raise capital as required, as to which no assurances can be provided. To address the additional funding requirements of the Company, management has undertaken the following initiatives: ● it has assessed its current expenditures and will be reducing the current spending requirements where necessary; ● it will pursue additional capital funding in the public and private markets through equity sales and/or debt facilities; ● it will pursue possible partnerships and collaborations; and ● it will pursue potential out licensing for its drug candidates. Our ability to continue as a going concern may depend on our ability to raise additional capital, attain further operating efficiencies, reduce expenditures, and, ultimately, to generate revenue. There are no assurances that these future funding and operating efforts will be successful. If management is unsuccessful in these efforts, our current capital is not expected to be sufficient to fund our operations for the next twelve months.

INVESTMENTS IN DEBT SECURITIES

INVESTMENTS IN DEBT SECURITIES AVAILABLE FOR SALE	12 Months Ended
	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
INVESTMENTS IN DEBT SECURITIES AVAILABLE FOR SALE	3. INVESTMENTS IN DEBT SECURITIES AVAILABLE FOR SALE Investments in debt securities available for sale with a fair value of $ 9,857,087 21,254,485 The Company reviews its debt securities classified as short-term investments on a regular basis for impairment. For debt securities in unrealized loss positions, the Company determines whether any portion of the decline in fair value below the amortized cost basis is due to credit-related factors if it neither intends to sell nor anticipates that it is more likely than not that it will be required to sell prior to recovery of the amortized cost basis. The Company considers factors such as the extent to which the market value has been less than the cost, any noted failure of the issuer to make scheduled payments, changes to the rating of the security and other relevant credit-related factors in determining whether or not a credit loss exists. During fiscal 2023 and 2022, the Company did not recognize an allowance for credit-related losses on any of our investments. A summary of the cost, fair value and maturities of the Company’s short-term investments is as follows: SCHEDULE OF COST, FAIR VALUE AND MATURITIES OF SHORT TERM INVESTMENTS December 31, 2023 December 31, 2022 Cost Fair Value Cost Fair Value Short-term investments U.S. Treasury securities $ 9,796,291 $ 9,857,087 $ - $ - Corporate debt securities - - 21,227,991 21,254,485 Total $ 9,796,291 $ 9,857,087 $ 21,227,991 $ 21,254,485 December 31, 2023 December 31, 2022 Cost Fair Value Cost Fair Value Short-term investment maturities Within 3 months $ 2,467,518 $ 2,490,775 $ 4,005,559 $ 3,994,590 Between 3-12 months 7,328,773 7,366,312 17,222,432 17,259,895 Total $ 9,796,291 $ 9,857,087 $ 21,227,991 $ 21,254,485 The following table shows the Company’s investment in debt securities available for sale gross unrealized gains (losses) and fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at December 31, 2023 and 2022. The Company has reviewed individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary. SUMMARY OF INVESTMENT SECURITIES GROSS UNREALIZED GAINS (LOSSES) December 31, 2023 December 31, 2022 Available for sale securities (all unrealized holding gains and losses are less than 12 months at date of measurement) Fair Value Unrealized Holding Gains (Losses) Fair Value Unrealized Holding Gains (Losses) Investments in debt securities with unrealized gains $ 9,857,087 $ 60,796 $ 13,278,505 $ 43,508 Investments in debt securities with unrealized losses - $ - 7,975,980 (17,014 ) Total $ 9,857,087 $ 60,796 $ 21,254,485 $ 26,494 Investment income, which includes net realized losses on sales of available for sale securities and investment income interest and dividends, is summarized as follows: SUMMARY OF NET REALIZED LOSSES ON SALES OF AVAILABLE FOR SALE SECURITIES AND INVESTMENT INCOME INTEREST AND DIVIDENDS 2023 2022 Interest and dividends accrued and paid $ 725,824 $ 502,578 Realized losses 431,801 (49,222 ) Realized gains (losses) 431,801 (49,222 ) Investment income, net $ 1,157,625 $ 453,356

RESTRICTED CASH

RESTRICTED CASH	12 Months Ended
	Dec. 31, 2023
Receivables [Abstract]
RESTRICTED CASH	4. RESTRICTED CASH As a condition of the SVB Loan Facility entered into on June 18, 2021, as further discussed in Note 9, the Company was required at all times to maintain on deposit with SVB as cash collateral in a segregated money market bank account in the name of the Company, unrestricted and unencumbered cash (other than a lien in favor of SVB) in an amount of at least 100% of the aggregate outstanding amount of the SVB loan facility. SVB could restrict withdrawals or transfers by or on behalf of the Company that would violate this requirement. The loan was repaid in full during the quarter ended June 30, 2023, thus removing this requirement. The required reserve totaled $ 6.0 The following table reconciles cash and cash equivalents and restricted cash per the consolidated balance sheets to the consolidated statements of cash flows: SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH December 31, 2023 December 31, 2022 Cash and cash equivalents $ 5,838,566 $ 11,492,841 Money market investments, restricted - 6,000,000 Total $ 5,838,566 $ 17,492,841

FAIR VALUES OF FINANCIAL INSTRU

FAIR VALUES OF FINANCIAL INSTRUMENTS	12 Months Ended
	Dec. 31, 2023
Fair Values Of Financial Instruments
FAIR VALUES OF FINANCIAL INSTRUMENTS	5. FAIR VALUES OF FINANCIAL INSTRUMENTS FASB ASC Section 820, Fair Value Measurements and Disclosures, Level 1: Quoted prices (unadjusted) or identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date; Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and Level 3: Significant unobservable inputs that reflect a reporting entity’s own assumptions that market participants would use in pricing an asset or liability. Cash and cash equivalents and accounts payable are reflected in the consolidated balance sheets at their approximate estimated fair values primarily due to their short-term nature. The fair values of securities available for sale are determined by relying on the securities’ relationship to other benchmark quoted securities and classified its investments as Level 2 items in both 2023 and 2022. There were no transfers of assets or liabilities between Level 1 and Level 2 and no transfers in or out of Level 3 during the years ended December 31, 2023 and 2022. The changes in Level 3 liabilities were the result of changes in the fair value of the earn-out milestone liability included in earnings and in-process R&D. The earnout milestone liability is valued using a risk-adjusted assessment of the probability of payment of each milestone, discounted to present value using an estimated time to achieve the milestone (see Note 13). Assets and liabilities measured at fair value are summarized below: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Total Fair Value Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs Assets: Recurring items as of December 31, 2023 Corporate debt securities, available for sale $ 9,857,087 $ 9,857,087 $ – $ – Recurring items as of December 31, 2022 Corporate debt securities and U.S. treasury obligations, available for sale $ 21,254,485 $ 21,254,485 $ – $ – Non-recurring items as of December 31, 2022 In-process R&D $ – $ – $ – $ – Liabilities: Recurring items as of December 31, 2022 Earn-out milestone liability $ - $ - $ - $ -

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	6. INTANGIBLE ASSETS In June 2014, the Company completed the acquisition of substantially all of the assets of EGEN, Inc., an Alabama corporation (“EGEN”), which changed its company name to EGWU, Inc. after the closing of the acquisition (the “EGEN Acquisition”). The Company acquired all of EGEN’s right, title and interest in and to substantially all of the assets of EGEN, including cash and cash equivalents, patents, trademarks and other intellectual property rights, clinical data, certain contracts, licenses and permits, equipment, furniture, office equipment, furnishings, supplies and other tangible personal property. In addition, CLSN Laboratories assumed certain specified liabilities of EGEN, including the liabilities arising out of the acquired contracts and other assets relating to periods after the closing date. Acquired In-process Research and Development. Acquired in-process research and development (“IPR&D”) consists of EGEN’s drug technology platforms: TheraPlas and TheraSilence. The fair value of the IPR&D drug technology platforms was estimated to be $ 24.2 As of December 31, 2022, the Company assessed whether there were indicators of impairment for the Company’s IPR&D and determined that the IPR&D asset was impaired during that period. Due to the continuing deterioration of public capital markets in the biotech industry in 2022 and 2021 and its impact on market capitalization rates in this sector, IPR&D was reviewed for impairment. Having conducted a quantitative analysis of the company’s IPR&D assets, the Company concluded the IPR&D asset was impaired during the fourth quarter of 2022. As of December 31, 2022, the Company wrote off the $ 13.4 13.4 The following is a summary of the net fair value of the assets acquired in the EGEN Acquisition for the year ended December 31, 2022: SCHEDULE OF FAIR VALUE OF ASSETS ACQUIRED IPR&D Balance at January 1, 2022, net $ 13,366,234 Balance $ 13,366,234 Impairment charge (13,366,234 ) Balance at December 31, 2022, net $ - Balance $ -

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	7. PROPERTY AND EQUIPMENT Property and equipment at December 31, 2023 and 2022 consist of the following: SUMMARY OF PROPERTY AND EQUIPMENT 2023 2022 December 31, 2023 2022 Machinery and equipment (5-7 year life) $ 2,055,192 $ 2,468,388 Machinery and equipment ( 5 7 $ 2,055,192 $ 2,468,388 Furniture and fixtures ( 3 5 191,932 350,481 Leasehold improvements ( 5 7 607,054 373,194 Property and equipment gross 2,854,178 3,192,063 Less accumulated depreciation and amortization (2,102,272 ) (2,643,762 ) Total $ 751,906 $ 548,301

OTHER ACCRUED LIABILITIES

OTHER ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
OTHER ACCRUED LIABILITIES	8. OTHER ACCRUED LIABILITIES Other accrued liabilities at December 31, 2023 and 2022 include the following: SCHEDULE OF OTHER ACCRUED LIABILITIES 2023 2022 December 31, 2023 2022 Amounts due to contract research organizations and other contractual agreements $ 1,442,659 $ 2,196,711 Accrued payroll and related benefits 1,693,383 2,139,927 Accrued interest - 37,583 Accrued professional fees 234,479 215,402 Other 20,000 205,313 Total $ 3,390,521 $ 4,794,936

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
NOTES PAYABLE	9. NOTES PAYABLE The SVB Loan Facility On June 18, 2021, the Company entered into a $ 10 6 10 5 6.0 The SVB Loan Facility was in the form of money market secured indebtedness bearing interest at a calculated WSJ Prime-based variable rate. A final payment equal to 3 10 Payments under the loan agreement were interest only for the first 24 months after loan closing, followed by a 24-month amortization period of principal and interest through the scheduled maturity date. In connection with the SVB Loan Facility, the Company incurred financing fees and expenses totaling $ 243,370 3.0 300,000 197,080 295,792 329,158 181,259 On April 21, 2023, the Company repaid the outstanding principal balance, an early termination fee and the end-of-term charges in full satisfaction of the SVB Loan Facility. The following is a schedule of the amounts paid to SVB on April 21, 2023: SCHEDULE OF DEBT Principal balance at April 21, 2023 $ 6,000,000 Early termination fees 120,000 End of term charges 300,000 Total payoff amount $ 6,420,000 During the year ended December 31, 2023, the Company recorded a loss of $ 329,158 334,212

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	10. INCOME TAXES The income tax benefit for the years ended December 31, 2023 and 2022 consists of the following: SCHEDULE OF INCOME TAX PROVISION (BENEFIT) 2023 2022 Federal Current $ - $ - Deferred - - State and Local - - Current - - Deferred (1,280,385 ) (1,567,026 ) Total $ (1,280,385 ) $ (1,567,026 ) A reconciliation of the Company’s statutory tax rate to the effective rate for the years ended December 31, 2023 and 2022 is as follows: SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION 2023 2022 Federal statutory rate 21.0 % 21.0 % State taxes, net of federal tax benefit 7.1 7.1 Permanent differences (3.1 ) 29.8 True-Up (105.0 ) – Other (2.9 ) – Change in valuation allowance and deferred rate change, net 89.0 (53.8 ) Effective tax rate 6.1 % 4.1 % The components of the Company’s deferred tax asset as of December 31, 2023 and 2022 are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2023 2022 December 31, 2023 2022 Net operating loss carryforwards $ 67,310,000 $ 79,800,000 Section 174 4,929,000 - Other deferred tax assets, net 2,016,000 13,287,000 Subtotal 74,255,000 93,087,000 Valuation allowance (72,974,615 ) (91,519,974 ) Total deferred tax asset $ 1,280,385 $ 1,567,026 The evaluation of the realizability of such deferred tax assets in future periods is made based upon a variety of factors that affect the Company’s ability to generate future taxable income, such as intent and ability to sell assets and historical and projected operating performance. The Company has established a valuation reserve for its deferred income tax assets other than those related to its New Jersey NOLs. At December 31, 2023, after its evaluation of its New Jersey NOLs as discussed more fully below, the Company reduced the valuation reserve and recognized $ 1.3 million as a deferred income tax asset. Such tax assets are available to be recognized and benefit future periods. As of December 31, 2023, the Company had federal net operating loss carryforwards of approximately $ 307 million, net of net operating losses utilized in prior years of which $ 218 million, if unused, will expire starting in 2024 through 2037. The federal NOLs generated for the years ended after 2017 of approximately $ 78 million can be carried forward indefinitely. As of December 31, 2023, the Company had state net operating loss carryforwards of approximately $ 44 million, net of net operating losses utilized in prior years, and, if unused, will expire starting in 2029 through 2042 . Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (“R&E”) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&E activities in the US must be amortized over a 5-year period if incurred, and R&E expenses incurred outside the US must be amortized over a 15-year period. R&E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&E capitalization and amortization to require it to pay cash taxes now or in the near future.The Company’s income tax returns for 2019 to 2022 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2023, and 2022, there were no unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next year. Sections 382 and 383 of the Internal Revenue Code provide for a limitation on the annual use of NOL and tax credit carryforwards following certain ownership changes that could limit the Company’s ability to utilize these carryforwards. The Company has completed an analysis to determine if such ownership changes have occurred and concluded it was more likely than not that there were changes in ownership. Due to the existence of full valuation allowance, limitations under Section 382 and 383 will not impact the Company’s effective tax rate. Further analyses will be performed prior to recognizing the benefits of any losses or credits in the financial statements. Sale of New Jersey Net Operating Losses Since 2018, the Company has annually submitted applications to sell a portion of the Company’s New Jersey NOLs as part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey-based companies. As part of the Technology Business Tax Certificate Program, the Company sold $ 1.3 million and $ 1.6 million of its New Jersey NOLs in 2023 and 2022, respectively. The sale of these net operating losses resulted in net proceeds to the Company of approximately $ 1.3 million in 2023 and $ 1.6 million in 2022. During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from $ 15 million to $ 20 million, which will allow the Company to participate in this funding program in future years for up to an additional $ 0.3 million in net operating losses under this maximum lifetime benefit.

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
STOCKHOLDERS’ EQUITY	11. STOCKHOLDERS’ EQUITY On March 19, 2021, the Company filed with the SEC a shelf registration statement on Form S-3 (the “2021 Registration Statement”) that allows the Company to issue any combination of common stock, preferred stock or warrants to purchase common stock or preferred stock in an amount up to $ 100 75 75 On September 19, 2022, the Company announced a corporate name change to Imunon, Inc. The Company’s common stock will continue to trade on the Nasdaq Stock Market under the new ticker symbol “IMNN” effective as of the opening of trading on September 21, 2022, and its CUSIP number (15117N602) remained unchanged. The Company filed an amendment to its Articles of Incorporation to effect the new corporate name. Reverse Stock Split On February 28, 2022, the Company effected a 15-for-1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on March 31, 2022. As of that date, each 15 shares of issued and outstanding common stock and equivalents was consolidated into one share of common stock. All shares have been restated to reflect the effects of the 15-for-1 reverse stock split. In addition, at the market open on March 1, 2022, the Company’s common stock started trading under a new CUSIP number 15117N602 although the Company’s ticker symbol, CLSN, remained unchanged. The reverse stock split was previously approved by the Company’s stockholders at the 2022 Special Meeting held on February 24, 2022, and the Company subsequently filed a Certificate of Amendment to its Certificate of Incorporation to effect the stock consolidation. The primary reasons for the reverse stock split and the amendment were: ● To provide the Company with the ability to support its future anticipated growth and would provide greater flexibility to consider and respond to future business opportunities and needs as they arise, including equity financings and stock-based acquisitions of new technology and product development candidates. The availability of additional shares of common stock would permit the Company to undertake certain of the foregoing actions without delay and expense associated with holding a Special Meeting of Stockholders to obtain stockholder approval each time such an opportunity arises that would require the issuance of shares of common stock; and ● To continue listing on The NASDAQ Capital Market, which requires that the Company comply with the applicable listing requirements under NASDAQ Marketplace Rules, which requirements include, among others, a minimum bid price of at least $1.00 per share. On December 2, 2021, the Company received a letter from NASDAQ indicating that the closing bid price of the Company’s common stock fell below $1.00 per share for the previous 30 consecutive business days, and that the Company was therefore not in compliance with the minimum bid price requirement for continued inclusion on The NASDAQ Capital Market. The Company had 180 calendar days, until May 31, 2022, to regain compliance with this requirement, which occurs when the closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of ten consecutive business days during the 180-day compliance period. Immediately prior to the reverse stock split, the Company had 86,557,736 5,770,516 The amount of the Company’s outstanding convertible preferred stock were not affected by the reverse stock split. 6.6 0.4 2.5 0.2 At the Market Offering Agreement On May 25, 2022, the Company entered into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which the Company may offer and sell, from time to time, through Wainwright, shares of the Company’s common stock having an aggregate offering price of up to $ 7,500,000 336,075 503,798 1,904,142 2,781,438 Series A and Series B Convertible Redeemable Preferred Stock Offering On January 10, 2022, the Company entered into a Securities Purchase Agreement (the “Preferred Stock Purchase Agreement”) with several institutional investors, pursuant to which the Company agreed to issue and sell, in concurrent registered direct offerings (the “Preferred Offerings”), (i) 50,000 0.01 50,000 0.01 285 5 300 14.25 28.50 300 13.65 1,098,901 300 15.00 1,000,000 On March 3, 2022, the Company redeemed for cash at a price equal to 105% of the $ 300 50,000 Series A Preferred Stock and its 50,000 In connection with the Preferred Offerings, the Company entered into a placement agent agreement (the “Placement Agent Agreement”) with AGP pursuant to which the Company agreed to pay AGP an aggregate cash fee equal to $ 1,000,000 110,000 April 2022 Registered Direct Offering On April 6, 2022, the Company entered into a Securities Purchase Agreement (the “April 2022 Purchase Agreement”) with several institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “April 2022 Offering”), an aggregate of 1,328,274 5.27 7.0 In connection with the April 2022 Offering, the Company entered into a placement agent agreement with A.G.P./Alliance Global Partners (the “April 2022 Placement Agent”) pursuant to which the Company agreed to pay the April 2022 Placement Agent a cash fee equal to 6.5% of the aggregate gross proceeds raised from the sale of the securities sold in the April 2022 Offering and reimburse the April 2022 Placement Agent for certain of their expenses in an amount not to exceed $50,000.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	12. STOCK-BASED COMPENSATION The Company has long-term compensation plans that permit the granting of equity-based awards in the form of stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, and performance awards. At the 2018 Annual Stockholders Meeting of the Company held on May 15, 2018, stockholders approved the Imunon, Inc. 2018 Stock Incentive Plan (the “2018 Plan”). The 2018 Plan, as adopted, permits the granting of 180,000 80,000 260,000 166,667 426,667 513,333 940,000 1,030,000 1,970,000 The Company has issued stock awards to employees and directors in the form of stock options and restricted stock. Options are generally granted with strike prices equal to the fair market value of a share of Imunon common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock of Imunon must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options. Option and restricted stock awards vest upon terms determined by the Compensation Committee of the Board of Directors and are subject to accelerated vesting in the event of a change of control or certain terminations of employment. The Company issues new shares to satisfy its obligations from the exercise of options or the grant of restricted stock awards. As of December 31, 2023, the Compensation Committee of the Board of Directors approved the grant of (i) inducement stock options (the “Inducement Option Grants”) to purchase a total of 294,751 91,350 1.59 As of December 31, 2023, there were a total of 1,975,073 768,731 1,206,342 294,751 Total compensation cost related to stock options and restricted stock awards was approximately $ 0.8 2.7 0.2 0.9 0.6 1.8 A summary of stock option awards as of December 31, 2023 and changes during the two-year period ended December 31, 2023 is presented below: SUMMARY OF STOCK OPTIONS Stock Options Number Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at January 1, 2022 441,425 $ 38.50 Options granted 716,156 $ 2.72 Options canceled or expired (397,361 ) $ 39.06 Outstanding at December 31, 2022 760,220 $ 4.55 Options granted 432,500 $ 1.23 Options canceled or expired (129,238 ) $ 9.37 Outstanding at December 31, 2023 1,063,482 $ 2.61 8.8 $ – Exercisable at December 31, 2023 453,766 $ 3.64 8.5 $ – A summary of the status of the Company’s non-vested restricted stock awards as of December 31, 2023 and changes during the two-year period ended December 31, 2023, is presented below: SUMMARY OF NON-VESTED RESTRICTED STOCK AWARDS Restricted Stock Number Outstanding Weighted Average Grant Date Fair Value Non-vested stock awards outstanding at January 1, 2022 1,481 $ 12.36 Granted 69,650 $ 1.92 Vested and issued (1,381 ) $ 12.04 Forfeited (100 ) $ 9.45 Non-vested stock awards outstanding at December 31, 2022 69,650 $ 1.92 Granted 22,100 $ 0.92 Vested and issued (59,450 ) $ 1.91 Forfeited (200 ) $ 4.60 Non-vested stock awards outstanding at December 31, 2023 32,100 $ 1.23 A summary of stock options outstanding at December 31, 2023 by price range is as follows: SUMMARY OF STOCK OPTIONS OUTSTANDING Options Outstanding Options Exercisable Range of Exercise Prices Number Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Number Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Up to $ 1.95 689,113 9.1 $ 1.74 315,867 8.8 $ 1.71 $ 1.96 10.00 347,975 8.4 $ 3.27 113,936 8.2 $ 4.63 Above $ 10.01 26,394 6.3 $ 23.69 23,963 6.1 $ 24.29 1,063,482 453,766 The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from Imunon’s stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model: SCHEDULE OF ASSUMPTIONS USED TO DETERMINE FAIR VALUE OF OPTIONS GRANTED Year Ended December 31, 2023 2022 Risk-free interest rate 3.39 4.81 % 1.74 3.97 % Expected volatility 100.0 113.6 % 100.0 113.9 % Expected life (in years) 7.5 10.0 7.5 10.0 Expected dividend yield 0.0 % 0.0 % Expected volatilities utilized in the model are based on historical volatility of the Company’s stock price. As of December 31, 2023, there was $ 0.4 1.8

EARN-OUT MILESTONE LIABILITY

EARN-OUT MILESTONE LIABILITY	12 Months Ended
	Dec. 31, 2023
Earn-out Milestone Liability
EARN-OUT MILESTONE LIABILITY	13. EARN-OUT MILESTONE LIABILITY The total aggregate purchase price for the EGEN Acquisition included potential future earn-out payments contingent upon achievement of certain milestones. The difference between the aggregate $ 30.4 13.9 each milestone (10% to 67%) and utilizing a discount rate based on the estimated time to achieve the milestone (1.5 to 2.5 years). On March 28, 2019, the Company and EGWU, Inc., entered into the Amended Asset Purchase Agreement. Pursuant to the Amended Asset Purchase Agreement, payment of the earnout milestone liability related to the Ovarian Cancer Indication of $ 12.4 a) $ 7.0 b) $ 12.4 At December 31, 2022, the Company wrote off the earn-out milestone liability as a result of the requirements not being achieved and recognized a non-cash gain of $ 5.4 The following is a summary of the changes in the earn-out milestone liability for 2022: SCHEDULE OF CHANGES IN EARN-OUT MILESTONE LIABILITY Balance at January 1, 2022 5,396,000 Non-cash gain from the adjustment for the change in fair value included in 2022 net loss (5,396,000 ) Balance at December 31, 2022 $ -

WARRANTS

WARRANTS	12 Months Ended
	Dec. 31, 2023
Warrants
WARRANTS	14. WARRANTS Following is a summary of all warrant activity for the two years ended December 31, 2023: SUMMARY OF WARRANT ACTIVITY Warrants Number of Warrants Issued Weighted Average Exercise Price Warrants outstanding at January 1, 2022 175,792 $ 20.96 Warrants expired during 2022 (7,273 ) $ 48.30 Warrants outstanding and exercisable at December 31, 2022 168,519 $ 19.78 Warrants expired during 2023 (8,459 ) $ 37.29 Warrants outstanding and exercisable at December 31, 2023 160,060 $ 18.86 Aggregate intrinsic value of outstanding warrants at December 31, 2023 $ - Weighted average remaining contractual terms (years) 2.2

IMUNON EMPLOYEE BENEFIT PLANS

IMUNON EMPLOYEE BENEFIT PLANS	12 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
IMUNON EMPLOYEE BENEFIT PLANS	15. IMUNON EMPLOYEE BENEFIT PLANS Imunon maintains a defined-contribution plan under Section 401(k) of the Code. The plan covers substantially all employees over the age of twenty-one. Participating employees may defer a portion of their pretax earnings, up to the IRS annual contribution limit. The Company makes a matching contribution up to a maximum of 3 142,000 117,000

LEASES

LEASES	12 Months Ended
	Dec. 31, 2023
Leases
LEASES	16. LEASES Lawrenceville, New Jersey Lease In August 2023, the Company renewed its Lawrenceville office lease for a 24 9,850 22,983 23,394 Huntsville, Alabama Lease In January 2023, the Company renewed its Huntsville facility lease for a 60 11,420 28,550 30,903 The following is a table of the lease payments and maturity of the Company’s operating lease liabilities as of December 31, 2023: SCHEDULE OF LEASE PAYMENTS AND MATURITY OF OPERATING LEASE LIABILITIES For the year ending December 31, 2024 $ 626,323 2025 543,009 2026 362,976 2027 370,236 2028 and Thereafter 30,903 Subtotal future lease payments 1,933,447 Less imputed interest (308,733 ) Total lease liabilities $ 1,624,714 Weighted average remaining life 3.5 Weighted average discount rate 9.98 % For 2023, operating lease expense was $ 646,633 644,593 587,744 601,495 472,000 535,000

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	17. COMMITMENTS AND CONTINGENCIES On October 29, 2020, a putative securities class action was filed against the Company and certain of its officers and directors (the “Spar Individual Defendants”) in the U.S. District Court for the District of New Jersey, captioned Spar v. Celsion Corporation, et al. In February 2021, a derivative shareholder lawsuit was filed against the Company, as the nominal defendant, and certain of its directors and officers as defendants in the U.S. District Court for the District of New Jersey, captioned Fidler v. Michael H. Tardugno, et al. ®.

TECHNOLOGY DEVELOPMENT AND LICE

TECHNOLOGY DEVELOPMENT AND LICENSING AGREEMENTS	12 Months Ended
	Dec. 31, 2023
Technology Development And Licensing Agreements
TECHNOLOGY DEVELOPMENT AND LICENSING AGREEMENTS	18. TECHNOLOGY DEVELOPMENT AND LICENSING AGREEMENTS On May 7, 2012, the Company entered into a long-term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. (“Hisun”) for the production of ThermoDox ® ® ® ® ® On January 18, 2013, the Company entered into a technology development contract with Hisun, pursuant to which Hisun paid Imunon a non-refundable research and development fee of $ 5 ® ® ® 5.0 10 ®

RELATED PARTY TRANSACTION

RELATED PARTY TRANSACTION	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTION	19. RELATED PARTY TRANSACTION On November 16, 2022 the Company entered into a convertible note purchase agreement with Transomic Technologies, Inc. (“Transomic”) whereby the Company purchased $ 375,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	20. SUBSEQUENT EVENTS On March 6, 2024, Dr. Corinne Le Goff, Pharm.D., informed the Board of Directors of her resignation from her position as President and Chief Executive Officer of the Company and from the Board, effective as of March 15, 2024. Dr. Le Goff’s resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. The Company is conducting a search for Dr. Le Goff’s successor as Chief Executive Officer. Michael H. Tardugno, the Company’s Executive Chairman, and Chief Executive Officer prior to Dr. Le Goff, has assumed day-to-day leadership of the Company until such successor is named and will continue in his role directing Company strategy.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Description of Business	Description of Business On September 19, 2022, Celsion Corporation announced a corporate name change to Imunon, Inc. (“Imunon” or the “Company”) reflecting the evolution of the Company’s business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company’s common stock continues to trade on the Nasdaq Stock Market under the ticker symbol “IMNN.” Imunon is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across four modalities. The first modality, TheraPlas ® ® ® ® The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting IND-enabling preclinical studies for the development of a COVID-19 booster vaccine (IMNN-101) and a treatment for the Lassa virus (IMNN-102). The Company has also initiated preclinical work to develop a Trp2 tumor associated antigen cancer vaccine in melanoma (IMNN-201). Imunon will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions.
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements (“Financial Statements”) of Imunon have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and CLSN Laboratories, Inc. The Company in 2023 dissolved Celsion GmbH. All significant intercompany balances and transactions have been eliminated in consolidation. Events and conditions arising subsequent to the most recent balance sheet date through the date of the issuance of these Financial Statements have been evaluated for their possible impact on the Financial Statements and accompanying notes. No events and conditions would give rise to any information that required accounting recognition or disclosure in the Financial Statements other than those arising in the ordinary course of business.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the earn-out milestone liabilities, estimates for contingent liabilities, if any, and accounting for impairment of in-process research and development assets. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.
Revenue Recognition	Revenue Recognition The Company’s sole revenue stream was related to the Hisun agreement described in Note 18, and whose contract has expired. There were no
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and investments purchased with an original maturity of three months or less. A portion of these funds are not covered by FDIC insurance.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying values of financial instruments approximate their respective fair values. Management believes that the carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments. Short-term investments are recorded at their estimated fair value.
Short-Term Investments	Short-Term Investments The Company classifies its investments in debt securities with readily determinable fair values as investments available-for-sale in accordance with Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided over the estimated useful lives of the related assets, ranging from three seven years 248,000 197,000 The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered impaired if its carrying amount exceeds the future net undiscounted cash flows that the asset is expected to generate. If such asset is considered to be impaired, the impairment recognized is the amount by which the carrying amount of the asset, if any, exceeds its fair value determined using a discounted cash flow model. There was no
Deposits	Deposits Deposits include real property security deposits and other deposits which are contractually required and of a long-term nature.
In-Process Research and Development, Other Intangible Assets and Goodwill	In-Process Research and Development, Other Intangible Assets and Goodwill During 2014, the Company acquired certain assets of EGEN, Inc. As more fully described in Note 6, the acquisition was accounted for under the acquisition method of accounting which required the Company to perform an allocation of the purchase price to the assets acquired and liabilities assumed. Under the acquisition method of accounting, the total purchase price is allocated to net tangible and intangible assets and liabilities based on their estimated fair values as of the acquisition date.
Impairment or Disposal of Long-Lived Assets	Impairment or Disposal of Long-Lived Assets The Company assesses the impairment of its long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. See Note 5 for information on impairment losses of its in -
Comprehensive Income (Loss)	Comprehensive Income (Loss) ASC 220, Comprehensive Income
Research and Development	Research and Development Research and development costs are expensed as incurred. Equipment and facilities acquired for research and development activities that have alternative future uses are capitalized and charged to expense over their estimated useful lives.
Net Loss per Share of Common Stock	Net Loss per Share of Common Stock Basic and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive. For the years ended December 31, 2023 and 2022, the total number of shares of common stock issuable upon exercise of warrants and equity awards was 1,255,642 988,389
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in results of operations in the period that the tax rate change occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In accordance with ASC 740, Income Taxes, As more fully discussed in Note 10, on November 28, 2023, the Company received approval from the New Jersey Economic Development Authority to sell $ 1.3 1.3 1.3 1.6 1.6 15 20 0.4
Stock-Based Compensation	Stock-Based Compensation In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, Compensation-Stock Compensation
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued accounting pronouncements will not have a material impact on the Company’s consolidated financial position, results of operations, and cash flows, or do not apply to its operations. In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures

INVESTMENTS IN DEBT SECURITIE_2

INVESTMENTS IN DEBT SECURITIES AVAILABLE FOR SALE (Tables)	12 Months Ended
	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
SCHEDULE OF COST, FAIR VALUE AND MATURITIES OF SHORT TERM INVESTMENTS	A summary of the cost, fair value and maturities of the Company’s short-term investments is as follows: SCHEDULE OF COST, FAIR VALUE AND MATURITIES OF SHORT TERM INVESTMENTS December 31, 2023 December 31, 2022 Cost Fair Value Cost Fair Value Short-term investments U.S. Treasury securities $ 9,796,291 $ 9,857,087 $ - $ - Corporate debt securities - - 21,227,991 21,254,485 Total $ 9,796,291 $ 9,857,087 $ 21,227,991 $ 21,254,485 December 31, 2023 December 31, 2022 Cost Fair Value Cost Fair Value Short-term investment maturities Within 3 months $ 2,467,518 $ 2,490,775 $ 4,005,559 $ 3,994,590 Between 3-12 months 7,328,773 7,366,312 17,222,432 17,259,895 Total $ 9,796,291 $ 9,857,087 $ 21,227,991 $ 21,254,485
SUMMARY OF INVESTMENT SECURITIES GROSS UNREALIZED GAINS (LOSSES)	The following table shows the Company’s investment in debt securities available for sale gross unrealized gains (losses) and fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at December 31, 2023 and 2022. The Company has reviewed individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary. SUMMARY OF INVESTMENT SECURITIES GROSS UNREALIZED GAINS (LOSSES) December 31, 2023 December 31, 2022 Available for sale securities (all unrealized holding gains and losses are less than 12 months at date of measurement) Fair Value Unrealized Holding Gains (Losses) Fair Value Unrealized Holding Gains (Losses) Investments in debt securities with unrealized gains $ 9,857,087 $ 60,796 $ 13,278,505 $ 43,508 Investments in debt securities with unrealized losses - $ - 7,975,980 (17,014 ) Total $ 9,857,087 $ 60,796 $ 21,254,485 $ 26,494
SUMMARY OF NET REALIZED LOSSES ON SALES OF AVAILABLE FOR SALE SECURITIES AND INVESTMENT INCOME INTEREST AND DIVIDENDS	Investment income, which includes net realized losses on sales of available for sale securities and investment income interest and dividends, is summarized as follows: SUMMARY OF NET REALIZED LOSSES ON SALES OF AVAILABLE FOR SALE SECURITIES AND INVESTMENT INCOME INTEREST AND DIVIDENDS 2023 2022 Interest and dividends accrued and paid $ 725,824 $ 502,578 Realized losses 431,801 (49,222 ) Realized gains (losses) 431,801 (49,222 ) Investment income, net $ 1,157,625 $ 453,356

RESTRICTED CASH (Tables)

RESTRICTED CASH (Tables)	12 Months Ended
	Dec. 31, 2023
Receivables [Abstract]
SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	The following table reconciles cash and cash equivalents and restricted cash per the consolidated balance sheets to the consolidated statements of cash flows: SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH December 31, 2023 December 31, 2022 Cash and cash equivalents $ 5,838,566 $ 11,492,841 Money market investments, restricted - 6,000,000 Total $ 5,838,566 $ 17,492,841

FAIR VALUES OF FINANCIAL INST_2

FAIR VALUES OF FINANCIAL INSTRUMENTS (Tables)	12 Months Ended
	Dec. 31, 2023
Fair Values Of Financial Instruments
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS	Assets and liabilities measured at fair value are summarized below: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Total Fair Value Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs Assets: Recurring items as of December 31, 2023 Corporate debt securities, available for sale $ 9,857,087 $ 9,857,087 $ – $ – Recurring items as of December 31, 2022 Corporate debt securities and U.S. treasury obligations, available for sale $ 21,254,485 $ 21,254,485 $ – $ – Non-recurring items as of December 31, 2022 In-process R&D $ – $ – $ – $ – Liabilities: Recurring items as of December 31, 2022 Earn-out milestone liability $ - $ - $ - $ -

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF FAIR VALUE OF ASSETS ACQUIRED	The following is a summary of the net fair value of the assets acquired in the EGEN Acquisition for the year ended December 31, 2022: SCHEDULE OF FAIR VALUE OF ASSETS ACQUIRED IPR&D Balance at January 1, 2022, net $ 13,366,234 Balance $ 13,366,234 Impairment charge (13,366,234 ) Balance at December 31, 2022, net $ - Balance $ -

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
SUMMARY OF PROPERTY AND EQUIPMENT	Property and equipment at December 31, 2023 and 2022 consist of the following: SUMMARY OF PROPERTY AND EQUIPMENT 2023 2022 December 31, 2023 2022 Machinery and equipment (5-7 year life) $ 2,055,192 $ 2,468,388 Machinery and equipment ( 5 7 $ 2,055,192 $ 2,468,388 Furniture and fixtures ( 3 5 191,932 350,481 Leasehold improvements ( 5 7 607,054 373,194 Property and equipment gross 2,854,178 3,192,063 Less accumulated depreciation and amortization (2,102,272 ) (2,643,762 ) Total $ 751,906 $ 548,301

OTHER ACCRUED LIABILITIES (Tabl

OTHER ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
SCHEDULE OF OTHER ACCRUED LIABILITIES	Other accrued liabilities at December 31, 2023 and 2022 include the following: SCHEDULE OF OTHER ACCRUED LIABILITIES 2023 2022 December 31, 2023 2022 Amounts due to contract research organizations and other contractual agreements $ 1,442,659 $ 2,196,711 Accrued payroll and related benefits 1,693,383 2,139,927 Accrued interest - 37,583 Accrued professional fees 234,479 215,402 Other 20,000 205,313 Total $ 3,390,521 $ 4,794,936

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
SCHEDULE OF DEBT	On April 21, 2023, the Company repaid the outstanding principal balance, an early termination fee and the end-of-term charges in full satisfaction of the SVB Loan Facility. The following is a schedule of the amounts paid to SVB on April 21, 2023: SCHEDULE OF DEBT Principal balance at April 21, 2023 $ 6,000,000 Early termination fees 120,000 End of term charges 300,000 Total payoff amount $ 6,420,000

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
SCHEDULE OF INCOME TAX PROVISION (BENEFIT)	The income tax benefit for the years ended December 31, 2023 and 2022 consists of the following: SCHEDULE OF INCOME TAX PROVISION (BENEFIT) 2023 2022 Federal Current $ - $ - Deferred - - State and Local - - Current - - Deferred (1,280,385 ) (1,567,026 ) Total $ (1,280,385 ) $ (1,567,026 )
SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION	A reconciliation of the Company’s statutory tax rate to the effective rate for the years ended December 31, 2023 and 2022 is as follows: SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION 2023 2022 Federal statutory rate 21.0 % 21.0 % State taxes, net of federal tax benefit 7.1 7.1 Permanent differences (3.1 ) 29.8 True-Up (105.0 ) – Other (2.9 ) – Change in valuation allowance and deferred rate change, net 89.0 (53.8 ) Effective tax rate 6.1 % 4.1 %
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	The components of the Company’s deferred tax asset as of December 31, 2023 and 2022 are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2023 2022 December 31, 2023 2022 Net operating loss carryforwards $ 67,310,000 $ 79,800,000 Section 174 4,929,000 - Other deferred tax assets, net 2,016,000 13,287,000 Subtotal 74,255,000 93,087,000 Valuation allowance (72,974,615 ) (91,519,974 ) Total deferred tax asset $ 1,280,385 $ 1,567,026

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
SUMMARY OF STOCK OPTIONS	A summary of stock option awards as of December 31, 2023 and changes during the two-year period ended December 31, 2023 is presented below: SUMMARY OF STOCK OPTIONS Stock Options Number Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at January 1, 2022 441,425 $ 38.50 Options granted 716,156 $ 2.72 Options canceled or expired (397,361 ) $ 39.06 Outstanding at December 31, 2022 760,220 $ 4.55 Options granted 432,500 $ 1.23 Options canceled or expired (129,238 ) $ 9.37 Outstanding at December 31, 2023 1,063,482 $ 2.61 8.8 $ – Exercisable at December 31, 2023 453,766 $ 3.64 8.5 $ –
SUMMARY OF NON-VESTED RESTRICTED STOCK AWARDS	A summary of the status of the Company’s non-vested restricted stock awards as of December 31, 2023 and changes during the two-year period ended December 31, 2023, is presented below: SUMMARY OF NON-VESTED RESTRICTED STOCK AWARDS Restricted Stock Number Outstanding Weighted Average Grant Date Fair Value Non-vested stock awards outstanding at January 1, 2022 1,481 $ 12.36 Granted 69,650 $ 1.92 Vested and issued (1,381 ) $ 12.04 Forfeited (100 ) $ 9.45 Non-vested stock awards outstanding at December 31, 2022 69,650 $ 1.92 Granted 22,100 $ 0.92 Vested and issued (59,450 ) $ 1.91 Forfeited (200 ) $ 4.60 Non-vested stock awards outstanding at December 31, 2023 32,100 $ 1.23
SUMMARY OF STOCK OPTIONS OUTSTANDING	A summary of stock options outstanding at December 31, 2023 by price range is as follows: SUMMARY OF STOCK OPTIONS OUTSTANDING Options Outstanding Options Exercisable Range of Exercise Prices Number Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Number Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Up to $ 1.95 689,113 9.1 $ 1.74 315,867 8.8 $ 1.71 $ 1.96 10.00 347,975 8.4 $ 3.27 113,936 8.2 $ 4.63 Above $ 10.01 26,394 6.3 $ 23.69 23,963 6.1 $ 24.29 1,063,482 453,766
SCHEDULE OF ASSUMPTIONS USED TO DETERMINE FAIR VALUE OF OPTIONS GRANTED	The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from Imunon’s stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model: SCHEDULE OF ASSUMPTIONS USED TO DETERMINE FAIR VALUE OF OPTIONS GRANTED Year Ended December 31, 2023 2022 Risk-free interest rate 3.39 4.81 % 1.74 3.97 % Expected volatility 100.0 113.6 % 100.0 113.9 % Expected life (in years) 7.5 10.0 7.5 10.0 Expected dividend yield 0.0 % 0.0 %

EARN-OUT MILESTONE LIABILITY (T

EARN-OUT MILESTONE LIABILITY (Tables)	12 Months Ended
	Dec. 31, 2023
Earn-out Milestone Liability
SCHEDULE OF CHANGES IN EARN-OUT MILESTONE LIABILITY	The following is a summary of the changes in the earn-out milestone liability for 2022: SCHEDULE OF CHANGES IN EARN-OUT MILESTONE LIABILITY Balance at January 1, 2022 5,396,000 Non-cash gain from the adjustment for the change in fair value included in 2022 net loss (5,396,000 ) Balance at December 31, 2022 $ -

WARRANTS (Tables)

WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2023
Warrants
SUMMARY OF WARRANT ACTIVITY	Following is a summary of all warrant activity for the two years ended December 31, 2023: SUMMARY OF WARRANT ACTIVITY Warrants Number of Warrants Issued Weighted Average Exercise Price Warrants outstanding at January 1, 2022 175,792 $ 20.96 Warrants expired during 2022 (7,273 ) $ 48.30 Warrants outstanding and exercisable at December 31, 2022 168,519 $ 19.78 Warrants expired during 2023 (8,459 ) $ 37.29 Warrants outstanding and exercisable at December 31, 2023 160,060 $ 18.86 Aggregate intrinsic value of outstanding warrants at December 31, 2023 $ - Weighted average remaining contractual terms (years) 2.2

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2023
Leases
SCHEDULE OF LEASE PAYMENTS AND MATURITY OF OPERATING LEASE LIABILITIES	The following is a table of the lease payments and maturity of the Company’s operating lease liabilities as of December 31, 2023: SCHEDULE OF LEASE PAYMENTS AND MATURITY OF OPERATING LEASE LIABILITIES For the year ending December 31, 2024 $ 626,323 2025 543,009 2026 362,976 2027 370,236 2028 and Thereafter 30,903 Subtotal future lease payments 1,933,447 Less imputed interest (308,733 ) Total lease liabilities $ 1,624,714 Weighted average remaining life 3.5 Weighted average discount rate 9.98 %

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Mar. 22, 2024	Nov. 28, 2023	Jan. 31, 2022
Property, Plant and Equipment [Line Items]
Accounts receivable	$ 0	$ 0
Depreciation expense	248,000	197,000
Impairment of property or equipment	$ 0	$ 0
Number of shares of common stock issuable upon exercise of warrants and equity awards	1,255,642	988,389
NEW JERSEY
Property, Plant and Equipment [Line Items]
Net proceeds from sale of net operating losses						$ 1,600,000
Tax benefits of EDA		$ 1,600,000
NEW JERSEY | New Jersey Division of Taxation [Member]
Property, Plant and Equipment [Line Items]
Net proceeds from sale of net operating losses	$ 1,300,000	$ 1,600,000			$ 1,300,000
NEW JERSEY | New Jersey Division of Taxation [Member] | Subsequent Event [Member]
Property, Plant and Equipment [Line Items]
Net proceeds from sale of net operating losses				$ 1,300,000
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	3 years
Minimum [Member] | NEW JERSEY
Property, Plant and Equipment [Line Items]
Net proceeds from sale of net operating losses			$ 15,000,000
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	7 years
Maximum [Member] | NEW JERSEY
Property, Plant and Equipment [Line Items]
Net proceeds from sale of net operating losses			20,000,000
Direct financing lease, selling loss			$ 400,000

FINANCIAL CONDITION AND GOING_2

FINANCIAL CONDITION AND GOING CONCERN UNCERTAINTY (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 19,514,977	$ 35,898,234
Fund operation	19,022,148	23,096,895
Cumulated net losses	388,182,802	$ 368,667,825
Cash and cash equivalents, short-term investments	15,700,000
Proceeds from sale of net operating losses	$ 1,300,000

SCHEDULE OF COST, FAIR VALUE AN

SCHEDULE OF COST, FAIR VALUE AND MATURITIES OF SHORT TERM INVESTMENTS (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Marketable Securities [Line Items]
Short-term investments - Cost	$ 9,796,291	$ 21,227,991
Short-term investments - Fair Value	9,857,087	21,254,485
Short-term investment maturities - Within 3 months, cost	2,467,518	4,005,559
Short-term investment maturities - Within 3 months, fair value	2,490,775	3,994,590
Short-term investment maturities - Between 3-12 months, cost	7,328,773	17,222,432
Short-term investment maturities - Between 3-12 months, fair value	7,366,312	17,259,895
Total, cost	9,796,291	21,227,991
Total, fair value	9,857,087	21,254,485
US Treasury Securities [Member]
Marketable Securities [Line Items]
Short-term investments - Cost	9,796,291
Short-term investments - Fair Value	9,857,087
Corporate Debt Securities [Member]
Marketable Securities [Line Items]
Short-term investments - Cost		21,227,991
Short-term investments - Fair Value		$ 21,254,485

SUMMARY OF INVESTMENT SECURITIE

SUMMARY OF INVESTMENT SECURITIES GROSS UNREALIZED GAINS (LOSSES) (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Investments with unrealized gains, Fair Value	$ 9,857,087	$ 13,278,505
Investments with unrealized gains, Unrealized Holding Gains (Losses)	60,796	43,508
Investments with unrealized losses, Fair Value		7,975,980
Investments with unrealized Losses, Unrealized Holding Gains (Losses)		(17,014)
Total, Fair Value	9,857,087	21,254,485
Total, Unrealized Holding Gains (Losses)	$ 60,796	$ 26,494

SUMMARY OF NET REALIZED LOSSES

SUMMARY OF NET REALIZED LOSSES ON SALES OF AVAILABLE FOR SALE SECURITIES AND INVESTMENT INCOME INTEREST AND DIVIDENDS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Interest and dividends accrued and paid	$ 725,824	$ 502,578
Realized gains (losses)	431,801	(49,222)
Investment income, net	$ 1,157,625	$ 453,356

INVESTMENTS IN DEBT SECURITIE_3

INVESTMENTS IN DEBT SECURITIES AVAILABLE FOR SALE (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Investment in debt securities - available for sale, at fair value	$ 9,857,087	$ 21,254,485

SCHEDULE OF CASH AND CASH EQUIV

SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Receivables [Abstract]
Cash and cash equivalents	$ 5,838,566	$ 11,492,841
Money market investments, restricted		6,000,000
Total	$ 5,838,566	$ 17,492,841

RESTRICTED CASH (Details Narrat

RESTRICTED CASH (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Line of Credit Facility [Line Items]
Restricted investments		$ 6,000,000
Silicon Valley Bank [Member]
Line of Credit Facility [Line Items]
Restricted investments		$ 6,000,000

SCHEDULE OF FAIR VALUE, ASSETS

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value	$ 9,857,087	$ 21,254,485
Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value		21,254,485
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out milestone liability
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out milestone liability
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out milestone liability
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out milestone liability
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value	9,857,087	21,254,485
Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value	9,857,087	21,254,485
Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value
Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value
Fair Value, Nonrecurring [Member] | Inprocess R&D [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value
Fair Value, Nonrecurring [Member] | Inprocess R&D [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value
Fair Value, Nonrecurring [Member] | Inprocess R&D [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value
Fair Value, Nonrecurring [Member] | Inprocess R&D [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value

SCHEDULE OF FAIR VALUE OF ASSET

SCHEDULE OF FAIR VALUE OF ASSETS ACQUIRED (Details) - IPR And D [Member]	12 Months Ended
	Dec. 31, 2022 USD ($)
Impairment Effects on Earnings Per Share [Line Items]
Balance	$ 13,366,234
Impairment charge	(13,366,234)
Balance

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - In Process Research and Development [Member] - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
EGEN Inc [Member] | IPR&D Drug Technology Platforms [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated acquisition price		$ 24.2
IPR&D Drug Technology Platforms [Member]
Finite-Lived Intangible Assets [Line Items]
Asset impairment charges			$ 13.4
Non-cash charge	$ 13.4

SUMMARY OF PROPERTY AND EQUIPME

SUMMARY OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 2,854,178	$ 3,192,063
Less accumulated depreciation and amortization	(2,102,272)	(2,643,762)
Total	751,906	548,301
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	2,055,192	2,468,388
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	191,932	350,481
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 607,054	$ 373,194

SUMMARY OF PROPERTY AND EQUIP_2

SUMMARY OF PROPERTY AND EQUIPMENT (Details) (Parenthetical)	Dec. 31, 2023
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years

SCHEDULE OF OTHER ACCRUED LIABI

SCHEDULE OF OTHER ACCRUED LIABILITIES (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Amounts due to contract research organizations and other contractual agreements	$ 1,442,659	$ 2,196,711
Accrued payroll and related benefits	1,693,383	2,139,927
Accrued interest		37,583
Accrued professional fees	234,479	215,402
Other	20,000	205,313
Total	$ 3,390,521	$ 4,794,936

SCHEDULE OF DEBT (Details)

SCHEDULE OF DEBT (Details) - Horizon Technology Finance Corporation [Member]	Apr. 21, 2023 USD ($)
Principal balance at April 21, 2023	$ 6,000,000
Early termination fees	120,000
End of term charges	300,000
Total payoff amount	$ 6,420,000

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)		1 Months Ended	12 Months Ended
	Jun. 18, 2021	Aug. 31, 2020	Dec. 31, 2023	Dec. 31, 2022
Line of Credit Facility [Line Items]
Interest expense debt			$ 197,080	$ 5,028,618
Silicon Valley Bank [Member]
Line of Credit Facility [Line Items]
Gain (loss) on contract termination			329,158
Silicon Valley Bank [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 10,000,000
Proceeds from lines of credit	6,000,000
Loan amount withdrawn		$ 10,000,000
Repayments of lines of credit		$ 5,000,000
Restricted cash	$ 6,000,000
Final payment percentage	3%
Long term line of credit	$ 10,000,000
Debt instrument, description	Payments under the loan agreement were interest only for the first 24 months after loan closing, followed by a 24-month amortization period of principal and interest through the scheduled maturity date.
Financing fees and expenses	$ 243,370
End of term charge percentage	3%
Interest expense debt	$ 300,000		334,212
Interest expense			197,080	295,792
Amortization of debt issuance costs			$ 329,158	$ 181,259

SCHEDULE OF INCOME TAX PROVISIO

SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Current
Deferred
State and Local
Current
Deferred	(1,280,385)	(1,567,026)
Total	$ (1,280,385)	$ (1,567,026)

SCHEDULE OF EFFECTIVE INCOME TA

SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Federal statutory rate	21%	21%
State taxes, net of federal tax benefit	7.10%	7.10%
Permanent differences	(3.10%)	29.80%
True-Up	(105.00%)
Other	(2.90%)
Change in valuation allowance and deferred rate change, net	89%	(53.80%)
Effective tax rate	6.10%	4.10%

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 67,310,000	$ 79,800,000
Section 174	4,929,000
Other deferred tax assets, net	2,016,000	13,287,000
Subtotal	74,255,000	93,087,000
Valuation allowance	(72,974,615)	(91,519,974)
Total deferred tax asset	$ 1,280,385	$ 1,567,026

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Nov. 28, 2023	Jan. 31, 2022	Dec. 31, 2018
Operating Loss Carryforwards [Line Items]
[custom:ProceedsFromSaleOfNetOperatingLosses]	$ 1,300,000
Deferred Tax Assets, Operating Loss Carryforwards	$ 67,310,000	$ 79,800,000
[custom:NetOperatingLossesExpirationDescription]	expire starting in 2029 through 2042
Income tax examination, description	Expenses incurred in connection with R&E activities in the US must be amortized over a 5-year period if incurred, and R&E expenses incurred outside the US must be amortized over a 15-year period. R&E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&E capitalization and amortization to require it to pay cash taxes now or in the near future.The Company’s income tax returns for 2019 to 2022 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years
Operating Income (Loss)	$ (21,030,430)	(24,921,565)
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	307,000,000
Net operating losses, unused	218,000,000
Federal Income Tax [Member] | No Expiration [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards						$ 78,000,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards	44,000,000
New Jersey [Member]
Operating Loss Carryforwards [Line Items]
[custom:ProceedsFromSaleOfNetOperatingLosses]	1,300,000
Net proceeds from sale of net operating losses	1,300,000	1,600,000
New Jersey [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating Income (Loss)			$ 300,000
New Jersey [Member] | State and Local Jurisdiction [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Net proceeds from sale of net operating losses			15,000,000
New Jersey [Member] | State and Local Jurisdiction [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Net proceeds from sale of net operating losses			20,000,000
NEW JERSEY
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards					$ 1,600,000
NEW JERSEY | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards			15,000,000
NEW JERSEY | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards			$ 20,000,000
NEW JERSEY | New Jersey Division of Taxation [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 1,300,000	$ 1,600,000		$ 1,300,000

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)					12 Months Ended
	May 25, 2022	Apr. 06, 2022	Jan. 10, 2022	Mar. 19, 2021	Dec. 31, 2023	Dec. 31, 2022	Mar. 03, 2022	Feb. 28, 2022	Jan. 13, 2022
Class of Stock [Line Items]
Stock issued during period, value, new issues					$ 2,781,438	$ 6,722,654
Reverse stock split, description					On February 28, 2022, the Company effected a 15-for-1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on March 31, 2022. As of that date, each 15 shares of issued and outstanding common stock and equivalents was consolidated into one share of common stock. All shares have been restated to reflect the effects of the 15-for-1 reverse stock split. In addition, at the market open on March 1, 2022, the Company’s common stock started trading under a new CUSIP number 15117N602 although the Company’s ticker symbol, CLSN, remained unchanged.
Stockholders equity note changes in capital structure description					To continue listing on The NASDAQ Capital Market, which requires that the Company comply with the applicable listing requirements under NASDAQ Marketplace Rules, which requirements include, among others, a minimum bid price of at least $1.00 per share. On December 2, 2021, the Company received a letter from NASDAQ indicating that the closing bid price of the Company’s common stock fell below $1.00 per share for the previous 30 consecutive business days, and that the Company was therefore not in compliance with the minimum bid price requirement for continued inclusion on The NASDAQ Capital Market. The Company had 180 calendar days, until May 31, 2022, to regain compliance with this requirement, which occurs when the closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of ten consecutive business days during the 180-day compliance period.
Common stock, shares outstanding					9,399,789	7,436,197		86,557,736
Reverse stock split					5,770,516
Preferred stock, shares issued					0	0
Preferred stock, stated value			$ 300		$ 0.01	$ 0.01	$ 300
Proceeds from issuance of preferred stock			$ 28,500,000
Preferred stock, shares outstanding					0	0
Proceeds from issuance under placement					$ 1,000,000
Proceeds from issuance of common stock					$ 2,781,438	$ 6,722,654
Series A Convertible Redeemable Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued			50,000
Preferred stock, stated value			$ 0.01
Share price			$ 300
Original issue discount rate			5%
Preferred stock, conversion price			$ 13.65
Conversion of stock, shares issued			1,098,901
Preferred stock, shares outstanding							50,000
Series B Convertible Redeemable Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued			50,000
Preferred stock, stated value			$ 0.01
Share price			$ 285						$ 300
Proceeds from issuance of preferred stock			$ 14,250,000
Preferred stock, conversion price									$ 15
Conversion of stock, shares issued									1,000,000
Preferred stock, shares outstanding							50,000
Market Offering Agreement [Member]
Class of Stock [Line Items]
Stock issued during period, value, new issues	$ 7,500,000
Number of shares sold					1,904,142	336,075
Proceeds from sale of stock					$ 2,781,438	$ 503,798
Securities Purchase Agreement [Member] | April 2022 Registered Direct Offering [Member]
Class of Stock [Line Items]
Share price		$ 5.27
Stock issued, shares		1,328,274
Proceeds from issuance of common stock		$ 7,000,000
Placement agent fee description		In connection with the April 2022 Offering, the Company entered into a placement agent agreement with A.G.P./Alliance Global Partners (the “April 2022 Placement Agent”) pursuant to which the Company agreed to pay the April 2022 Placement Agent a cash fee equal to 6.5% of the aggregate gross proceeds raised from the sale of the securities sold in the April 2022 Offering and reimburse the April 2022 Placement Agent for certain of their expenses in an amount not to exceed $50,000.
Maximum [Member]
Class of Stock [Line Items]
Common stock, shares outstanding					6,600,000
Warrants issued					2,500,000
Proceeds from issuance under placement					$ 110,000
Minimum [Member]
Class of Stock [Line Items]
Common stock, shares outstanding					400,000
Warrants issued					200,000
2021 Registration Statement [Member]
Class of Stock [Line Items]
Stock issued during period, value, new issues				$ 100,000,000
Public float				75,000,000
2021 Registration Statement [Member] | Baby Shelf Limitation [Member]
Class of Stock [Line Items]
Public float				$ 75,000,000

SUMMARY OF STOCK OPTIONS (Detai

SUMMARY OF STOCK OPTIONS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number Outstanding, Outstanding, Ending balance	1,063,482
Number Outstanding, Exercisable, Ending balance	453,766
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number Outstanding, Outstanding, Beginning balance	760,220	441,425
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 4.55	$ 38.50
Number Outstanding, Options granted	432,500	716,156
Weighted Average Exercise Price, Options granted	$ 1.23	$ 2.72
Number Outstanding, Options canceled or expired	(129,238)	(397,361)
Weighted Average Exercise Price, Options canceled or expired	$ 9.37	$ 39.06
Number Outstanding, Outstanding, Ending balance	1,063,482	760,220
Weighted Average Exercise Price, Outstanding, Ending balance	$ 2.61	$ 4.55
Weighted Average Remaining Contractual Term (years), Outstanding, Ending balance	8 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding, Ending balance
Number Outstanding, Exercisable, Ending balance	453,766
Weighted Average Exercise Price, Exercisable, Ending balance	$ 3.64
Weighted Average Remaining Contractual Term (years), Exercisable, Ending balance	8 years 6 months
Aggregate Intrinsic Value, Exercisable, Ending balance

SUMMARY OF NON-VESTED RESTRICTE

SUMMARY OF NON-VESTED RESTRICTED STOCK AWARDS (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Number Outstanding, Non-vested stock awards, Outstanding, Beginning balance	69,650	1,481
Weighted Average Grant Date Fair Value, Non-vested stock awards, Outstanding, Beginning balance	$ 1.92	$ 12.36
Number Outstanding, Non-vested stock awards, Granted	22,100	69,650
Weighted Average Grant Date Fair Value, Non-vested stock awards, Granted	$ 0.92	$ 1.92
Number Outstanding, Non-vested stock awards, Vested and issued	(59,450)	(1,381)
Weighted Average Grant Date Fair Value, Non-vested stock awards, Vested and issued	$ 1.91	$ 12.04
Number Outstanding, Non-vested stock awards, Forfeited	(200)	(100)
Weighted Average Grant Date Fair Value, Non-vested stock awards, Forfeited	$ 4.60	$ 9.45
Number Outstanding, Non-vested stock awards, Outstanding, Ending balance	32,100	69,650
Weighted Average Grant Date Fair Value, Non-vested stock awards, Outstanding, Ending balance	$ 1.23	$ 1.92

SUMMARY OF STOCK OPTIONS OUTSTA

SUMMARY OF STOCK OPTIONS OUTSTANDING (Details)	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number | shares	1,063,482
Options Exercisable, Number | shares	453,766
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, Upper	$ 1.95
Options Outstanding, Number | shares	689,113
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	9 years 1 month 6 days
Options Outstanding, Weighted Average Exercise Price	$ 1.74
Options Exercisable, Number | shares	315,867
Options Exercisable, Weighted Average Remaining Contractual Term (in years)	8 years 9 months 18 days
Options Exercisable, Weighted Average Exercise Price	$ 1.71
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, Upper	$ 10
Options Outstanding, Number | shares	347,975
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	8 years 4 months 24 days
Options Outstanding, Weighted Average Exercise Price	$ 3.27
Options Exercisable, Number | shares	113,936
Options Exercisable, Weighted Average Remaining Contractual Term (in years)	8 years 2 months 12 days
Options Exercisable, Weighted Average Exercise Price	$ 4.63
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit	1.96
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, Upper	$ 10.01
Options Outstanding, Number | shares	26,394
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	6 years 3 months 18 days
Options Outstanding, Weighted Average Exercise Price	$ 23.69
Options Exercisable, Number | shares	23,963
Options Exercisable, Weighted Average Remaining Contractual Term (in years)	6 years 1 month 6 days
Options Exercisable, Weighted Average Exercise Price	$ 24.29

SCHEDULE OF ASSUMPTIONS USED TO

SCHEDULE OF ASSUMPTIONS USED TO DETERMINE FAIR VALUE OF OPTIONS GRANTED (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate, minimum	3.39%	1.74%
Risk-free interest rate, maximum	4.81%	3.97%
Expected volatility, minimum	100%	100%
Expected volatility, maximum	113.60%	113.90%
Expected dividend yield	0%	0%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected life (in years)	7 years 6 months	7 years 6 months
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected life (in years)	10 years	10 years

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details Narrative) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Jun. 14, 2023	Jun. 10, 2021	Jun. 15, 2020	May 14, 2019	May 15, 2018
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost	$ 0.4
Cost recognized over a weighted-average period	1 year 9 months 18 days
Equity Stock Awards [Member] | Granted Under 2018 Plan and 2007 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, reserved for future issuance	768,731
Inducement Awards [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, reserved for future issuance	294,751
Stock Options and Restricted Stock Awards [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation	$ 0.8	$ 2.7
Stock Options and Restricted Stock Awards [Member] | Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation	0.2	0.9
Stock Options and Restricted Stock Awards [Member] | General and Administrative Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation	$ 0.6	$ 1.8
2018 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based payment award, shares authorized							180,000
Shares available for issuance	1,206,342
Stock options, strike price description	Options are generally granted with strike prices equal to the fair market value of a share of Imunon common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock of Imunon must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options.
Common stock, reserved for future issuance	1,975,073
2018 Stock Incentive Plan [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares available for issuance			1,030,000	513,333	166,667	80,000
2018 Stock Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares available for issuance			1,970,000	940,000	426,667	260,000
Inducement Option Grants [Member] | Five New Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price per share	$ 1.59
Inducement Option Grants [Member] | Five New Employees [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock	91,350
Inducement Option Grants [Member] | Five New Employees [Member] | Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock	294,751

SCHEDULE OF CHANGES IN EARN-OUT

SCHEDULE OF CHANGES IN EARN-OUT MILESTONE LIABILITY (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)
Earn-out Milestone Liability
Earn-out liabilities, beginning balance	$ 5,396,000
Non-cash gain loss from the adjustment for the change in fair value	(5,396,000)
Earn-out liabilities, ending balance

EARN-OUT MILESTONE LIABILITY (D

EARN-OUT MILESTONE LIABILITY (Details Narrative) - USD ($) $ in Millions		12 Months Ended
	Jun. 20, 2014	Dec. 31, 2022	Mar. 28, 2019
EGWC, Inc [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Earnout payment options description	each milestone (10% to 67%) and utilizing a discount rate based on the estimated time to achieve the milestone (1.5 to 2.5 years).
Non-cash charge on earnout milestone liability		$ 5.4
Amended Asset Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Earnout milestone liability	$ 13.9		$ 12.4
Amended Asset Purchase Agreement [Member] | Within One Year of Achieving Milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Earnout milestone liability	$ 30.4
Amended Asset Purchase Agreement [Member] | 10 Business Days of Achieving Milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Earnout milestone liability			$ 7

SUMMARY OF WARRANT ACTIVITY (De

SUMMARY OF WARRANT ACTIVITY (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Warrants
Number of Warrants Issued, Warrants outstanding, Beginning balance	168,519	175,792
Weighted Average Exercise Price, Warrants outstanding, Beginning balance	$ 19.78	$ 20.96
Number of Warrants Issued, warrants expired	(8,459)	(7,273)
Weighted Average Exercise Price, Warrants expired	$ 37.29	$ 48.30
Number of Warrants Issued, Warrants outstanding, Ending balance	160,060	168,519
Weighted Average Exercise Price, Warrants outstanding, Ending balance	$ 18.86	$ 19.78
Aggregate intrinsic value of outstanding warrants
Weighted average remaining contractual terms (years)	2 years 2 months 12 days

IMUNON EMPLOYEE BENEFIT PLANS (

IMUNON EMPLOYEE BENEFIT PLANS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Retirement Benefits [Abstract]
Maximum annual contributions per employee, percent	3%
Matching contributions of employee	$ 142,000	$ 117,000

SCHEDULE OF LEASE PAYMENTS AND

SCHEDULE OF LEASE PAYMENTS AND MATURITY OF OPERATING LEASE LIABILITIES (Details)	Dec. 31, 2023 USD ($)
Leases
2024	$ 626,323
2025	543,009
2026	362,976
2027	370,236
2028 and Thereafter	30,903
Subtotal future lease payments	1,933,447
Less imputed interest	(308,733)
Total lease liabilities	$ 1,624,714
Operating lease, weighted average remaining lease term	3 years 6 months
Operating lease, weighted average discount rate, percent	9.98%

LEASES (Details Narrative)

LEASES (Details Narrative)	1 Months Ended		12 Months Ended
	Aug. 31, 2023 USD ($) ft²	Jan. 31, 2023 USD ($) ft²	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease, term	24 months	60 months
Operating lease, cost			$ 646,633	$ 587,744
Operating lease, payments			644,593	601,495
Amortization expense			$ 472,000	$ 535,000
Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Area of land | ft²	9,850	11,420
Lease Agreement [Member] | Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for rent	$ 22,983	$ 28,550
Lease Agreement [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for rent	$ 23,394	$ 30,903

TECHNOLOGY DEVELOPMENT AND LI_2

TECHNOLOGY DEVELOPMENT AND LICENSING AGREEMENTS (Details Narrative) - Hisun [Member] $ in Millions	Jan. 18, 2013 USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Proceeds from license fees received	$ 5
Deferred revenue	$ 5
Deferred revenue amortization period	10 years

RELATED PARTY TRANSACTION (Deta

RELATED PARTY TRANSACTION (Details Narrative)	Nov. 16, 2022 USD ($)
Convertible Note Purchase Agreement [Member] | Transomic Technologies, Inc. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Convertable and warrants	$ 375,000